India’s Drug Watchdog Speeds Up Regulatory Overhaul
This article was originally published in The Pink Sheet Daily
Single window drug clearance, replacing at lest six government departments, to precede central drug authority.
You may also be interested in...
Sweeping Changes In India’s Clinical Trial Laws Could Allow Phase I MNC Studies Under Certain Circumstances
MUMBAI - Conducting clinical trials in India may get a little easier for multinational drug companies. That is because the much-awaited amendments to the contentious "Schedule Y" of India's Drug and Cosmetics Act have moved one step forward
“The goal is to ensure that any drug approved in India should directly be approved by the U.S. FDA,” health minister says.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.